N-(2,4-difluorophenyl)-N'-(4-((6,7-dimethoxy-4-quinolyl)oxy)-2-fluorophenyl)urea: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11317348 |
| CHEMBL ID | 178455 |
| CHEBI ID | 92822 |
| SCHEMBL ID | 1249562 |
| MeSH ID | M0483050 |
| Synonym |
|---|
| HY-12038 |
| HMS3269O17 |
| BRD-K47150025-001-01-2 |
| NCGC00167768-01 |
| 1-(2,4-difluoro-phenyl)-3-[4-(6,7-dimethoxy-quinolin-4-yloxy)-2-fluoro-phenyl]-urea |
| bdbm50162147 |
| CHEMBL178455 , |
| 1-(2,4-difluorophenyl)-3-(4-(6,7-dimethoxyquinolin-4-yloxy)-2-fluorophenyl)urea |
| KI 8751 , |
| BCP9000009 |
| 228559-41-9 |
| KI8751 , |
| BCP0726000123 |
| NCGC00167768-02 |
| CS-0190 |
| n-(2,4-difluorophenyl)-n'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]urea |
| MLS006011284 |
| smr004703034 |
| SCHEMBL1249562 |
| tert-butyl2-bromobutyrate |
| 1-(2,4-difluorophenyl)-3-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-fluorophenyl)urea |
| AC-30283 |
| AKOS024457157 |
| ki-8751 |
| n-(2,4-difluorophenyl)-n'-(4-((6,7-dimethoxy-4-quinolyl)oxy)-2-fluorophenyl)urea |
| EX-A227 |
| DTXSID60462145 |
| 1-(2,4-difluorophenyl)-3-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-fluorophenyl]urea |
| CHEBI:92822 |
| HMS3654B19 |
| J-014880 |
| mfcd09971092 |
| SW218156-2 |
| BCP02842 |
| 1-(2,4-difluorophenyl)-3-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]urea |
| Q27164581 |
| vegfr2 kinase inhibitor vi, ki8751 - cas 228559-41-9 |
| n-(2,4-difluorophenyl)-n'-[4-[(6,7-dimethoxy-4-quinolin yl)oxy]-2-fluorophenyl]urea |
| S1363 |
| FT-0704656 |
| HMS3677F19 |
| AS-19388 |
| HMS3413F19 |
| SB19355 |
| CCG-269442 |
| rp6ugt29ff , |
| unii-rp6ugt29ff |
| urea, n-(2,4-difluorophenyl)-n'-(4-((6,7-dimethoxy-4-quinolinyl)oxy)-2-fluorophenyl)- |
| n-(2,4-difluorophenyl)-n'-(4-((6,7-dimethoxy-4-quinolinyl)oxy)-2-fluorophenyl)urea |
| 1-(2,4-difluorophenyl)-3-(4-(6,7-dimethoxyquinolin-4-yl)oxy-2-fluorophenyl)urea |
| NCGC00167768-11 |
| Excerpt | Reference |
|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) |
| Class | Description |
|---|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Fumarate hydratase | Homo sapiens (human) | Potency | 37.2212 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| PPM1D protein | Homo sapiens (human) | Potency | 10.4353 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 14.7485 | 0.0013 | 10.1577 | 42.8575 | AID1259252; AID1259253; AID1259255; AID1259256 |
| polyprotein | Zika virus | Potency | 37.2212 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 17.7828 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| Interferon beta | Homo sapiens (human) | Potency | 10.4353 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0000 | 0.5369 | 10.0000 | AID241262; AID241322 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0004 | 0.3722 | 10.0000 | AID241358 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | IC50 (µMol) | 0.0400 | 0.0007 | 0.4708 | 10.0000 | AID241626 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | IC50 (µMol) | 0.0670 | 0.0001 | 0.4912 | 10.0000 | AID241725 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.1700 | 0.0004 | 0.3276 | 8.6200 | AID241407 |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0025 | 3.0926 | 9.5820 | AID241264 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 2.4000 | 0.0003 | 0.3887 | 7.0000 | AID1129405 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.8016 | 0.0000 | 0.4830 | 8.8000 | AID1129405; AID241663; AID241726 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 2.4000 | 0.0003 | 0.7123 | 7.0700 | AID1129405 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 2.4000 | 0.0002 | 0.6603 | 10.0000 | AID1129405 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID241262 | Inhibition of epidermal growth factor receptor in cell-free assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID241663 | Inhibition of vascular endothelial growth factor receptor 2 in cell-free assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID245810 | Tumor growth inhibition ratio against DLD-1 tumor cells after oral administration at 20 mg/kg/day | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID1129404 | Growth inhibition of HUVEC by WST-8 assay | 2014 | Journal of natural products, Apr-25, Volume: 77, Issue:4 | Potential anti-angiogenesis effects of p-terphenyl compounds from Polyozellus multiplex. |
| AID646188 | Antiangiogenic activity in HUVEC assessed as inhibition of cell proliferation after 72 hrs by MTT assay | 2012 | Journal of natural products, Jan-27, Volume: 75, Issue:1 | Hypoxylonols C-F, benzo[j]fluoranthenes from Hypoxylon truncatum. |
| AID241407 | Inhibition of fibroblast growth factor receptor 2 in cell-intact assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID241626 | Inhibition of proto-oncogene tyrosine-protein kinase kit in cell-intact assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID241322 | Inhibition of epidermal growth factor receptor in cell-intact assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID241725 | Inhibition of platelet-derived growth factor receptor alpha in cell-intact assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID241358 | Inhibition of hepatocyte growth factor receptor in cell-intact assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID240750 | Inhibition of protein kinase A in cell-free assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID646189 | Antiangiogenic activity in HUAEC assessed as inhibition of cell proliferation after 72 hrs by MTT assay | 2012 | Journal of natural products, Jan-27, Volume: 75, Issue:1 | Hypoxylonols C-F, benzo[j]fluoranthenes from Hypoxylon truncatum. |
| AID241264 | Inhibition of mitogen activated protein kinase in cell-free assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID240922 | Inhibition of protein kinase C alpha in cell-free assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID240802 | Inhibition of Insulin receptor in cell-intact assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID1129405 | Inhibition of recombinant human VEGFR2 | 2014 | Journal of natural products, Apr-25, Volume: 77, Issue:4 | Potential anti-angiogenesis effects of p-terphenyl compounds from Polyozellus multiplex. |
| AID245809 | Tumor growth inhibition ratio against St-4 tumor cells after oral administration at 20 mg/kg/day | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID241726 | Inhibition of vascular endothelial growth factor receptor 2 in cell-intact assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID241528 | Inhibition of mitogen activated protein kinase kinase 1 in cell-free assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID245806 | Tumor growth inhibition ratio against A375 tumor cells after oral administration at 20 mg/kg/day | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID245808 | Tumor growth inhibition ratio against LC-6 tumor cells after oral administration at 20 mg/kg/day | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID245807 | Tumor growth inhibition ratio against GL07 tumor cells after oral administration at 20 mg/kg/day | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID240885 | Inhibition of c-Src tyrosine kinase in cell-free assay | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5 | Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 7 (36.84) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||